Patients with HER2-low disease had significantly worse PFS when compared to patients with HER2-0 BC (median PFS [range]: 23.6 months [18.9–28.1] vs. 32.3 months [26.1-NA]; p = 0.014) (Fig. 1). Here, ERBB2 is linked to breast cancer.